Clinical Trial Update: Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME) [Phase 1]

View source ↗

Summary

Regeneron reports the completion of a Phase 1 study evaluating intravitreal REGN910-3 and REGN910 for neovascular age-related macular degeneration and diabetic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• REGN910
• REGN910-3

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema | Phase 1 | Status: COMPLETED